We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
REO-001: A phase I trial of percutaneous intralesional administration of reovirus type 3 dearing (Reolysin®) in patients with advanced solid tumors.
- Authors
Morris, Don G; Feng, Xiaolan; DiFrancesco, Lisa M; Fonseca, Kevin; Forsyth, Peter A; Paterson, Alexander H; Coffey, Matt C; Thompson, Brad
- Abstract
This open-labeled, phase I clinical trial was designed to determine the safety and tolerability of percutaneous intralesional administration of wild-type oncolytic revovirus type 3 Dearing (Reolysin®) in cancer patients with accessible and evaluable disease, who had otherwise failed to improve on standard cancer interventions.
- Publication
Investigational new drugs, 2013, Vol 31, Issue 3, p696
- ISSN
1573-0646
- Publication type
Journal Article
- DOI
10.1007/s10637-012-9865-z